The only FDA-cleared Pneumonia panel that detects Pneumocystis jirovecii.

Specimen Types:
- Endotracheal Aspirate
- Bronchoalveolar Lavage (including mini-BAL)

Comprehensive Testing Panel

FDA-cleared Unyvero uniquely and accurately detects the most clinically relevant pathogens and antibiotic resistance markers associated with pneumonia.

<table>
<thead>
<tr>
<th>BACTERIA</th>
<th>RESISTANCE</th>
<th>GENES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acinetobacter spp.</td>
<td>Moraxella catarrhalis</td>
<td>kpc</td>
</tr>
<tr>
<td>Chlamydia pneumoniae</td>
<td>Morganella morganii</td>
<td>ndm</td>
</tr>
<tr>
<td>Citrobacter freundii</td>
<td>Mycoplasma pneumoniae</td>
<td>oxa-23</td>
</tr>
<tr>
<td>Enterobacter cloacae complex</td>
<td>Proteus spp.</td>
<td>oxa-24</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>Pseudomonas aeruginosa</td>
<td>oxa-48</td>
</tr>
<tr>
<td>Haemophilus influenzae</td>
<td>Serratia marcescens</td>
<td>ndm</td>
</tr>
<tr>
<td>Klebsiella oxytoca</td>
<td>Staphylococcus aureus</td>
<td>oxa-58</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>Stenotrophomonas maltophilia</td>
<td>vim</td>
</tr>
<tr>
<td>Klebsiella variicola</td>
<td>Streptococcus pneumoniae</td>
<td></td>
</tr>
<tr>
<td>Legionella pneumophila</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| FUNGI                                         |            |        |
| Pneumocystis jirovecii *                      |            |        |

* included on the Unyvero LRT BAL panel.

- Rapid, sample-to-answer
- Direct from specimen
- Simple and clear qualitative results based on quantitative algorithms
- Critical information for life-saving treatment decisions

One patient sample. Comprehensive results. Unyvero points the way.
CLEAR DIRECTION for hospitalized pneumonia patients

Pneumonia can be fatal
Clinical outcomes are highly dependent upon timely and appropriate therapy. Unfortunately, standard of care microbiology has a number of limitations, including:

- Takes several days to get results
- Fails to determine a causative agent in >50% of pneumonia patients
- Affected by sample transport time
- Exposure to unnecessary broad-spectrum antibiotics

Unyvero is Changing the Status Quo

Greater Diagnostic Accuracy Can Save Lives
Unyvero LRT has demonstrated correct identification of key pathogens that are often missed by culture, without relying on the growth of viable organisms.

Unyvero LRT identified *Acinetobacter* cases that were initially culture-negative but all had a subsequent culture that grew *Acinetobacter*. All patients with initial negative culture for *Acinetobacter* died.

Potential Impact on Antibiotic Therapy

- Unyvero panel favors narrowing over expanding antibiotic coverage nearly 2-fold (29% vs. 15%).
- Unyvero could potentially optimize antibiotic therapy in >50% of cases.

Get Clear Direction
Unyvero LRT quickly delivers actionable answers to reduce the time to appropriate therapy and drive optimal, cost-effective care for hospitalized pneumonia patients. For clear, comprehensive, and reliable results to advance antimicrobial stewardship initiatives, Unyvero points the way.

Request an evaluation today: curetisusa.com | info_us@curetis.com

References:

© 2020 Curetis USA, Inc. All rights reserved. Unyvero is a registered trademark of Curetis GmbH. 00589 Rev. 4.0